ALK population
-
3-5% of NSCLC
-
Adenocarcinoma, younger patients and never smokers
-
60-70 % of pts have brain metastases at any time of the disease
-
Testing: FISH, IHC or NGS
-
Crizotinib Ph 1 results: ORR=61%, median time to response 7,6w
PFS=9,7 m
Toxicity profile: visual effects, N/V,
diarrhoea, peripheral edema
Kwak NEJM 2010; Camidge R, et al Lancet Oncol 2012; Costa et al. J Clin Oncol 2015
